Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Endocrinology is off to a stellar start in 2026, with a first quarter packed full of major FDA approvals and trial results. Orforglipron, now approved for 

, demonstrated some of its best trial performance in February, while the investigational triple agonist retatrutide demonstrated solid safety data in the same disease. Meanwhile, the 

 fired off a volley of approvals, covering the first once-weekly basal insulin for T2D, inhaled insulin powder for 

, and setmelanotide for the rare and previously poorly-managed acquired hypothalamic 

With so much practice-changing news arriving over the last 3 months, 

 has collected 9 of the most impactful headlines from this first quarter. Catch up on any big news you may have missed below:


FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes


On March 26, 2026, the FDA approved insulin icodec-abae as the first and only once-weekly basal insulin for the improvement of glycemic control as an adjunct to diet and exercise in patients with T2D. Under the brand name Awiqli, this is the first new class of basal insulin to reach US patients in over 2 decades. The approval was based on the ONWARDS clinical program, including 4 clinical trials evaluating insulin icodec against standard once-daily basal insulins.


FDA Approves Setmelanotide (Imcivree) for Acquired Hypothalamic Obesity


On March 19, 2026, the FDA announced its approval of an expanded indication for setmelanotide, allowing its use for the treatment of hypothalamic obesity in adults and pediatric patients aged ≥4 years. Based on data from the phase 3 TRANSCEND trial, which demonstrated setmelanotide’s greater body mass index (BMI) reducing capacity compared to placebo, setmelanotide is a major step forward for a historically rare disease with very few options for treatment.


FDA Approves Updated Starting Dose Guidelines for Inhaled Insulin Powder (Afrezza)


On January 26, 2026, parent company MannKind Corporation announced the FDA’s approval of an updated label for insulin human inhalation powder (Afrezza), providing guidance for starting doses when switching from multiple daily injections or insulin pump mealtime therapy in patients with T1D. The decision was in part due to the phase 4 INHALE-3 trial, which demonstrated improved postprandial glucose outcomes after converting to inhaled insulin with the new dose.


FDA Clears MiniMed Go Smart MDI App for Adults and Children with T1D, T2D


On January 12, 2026, Medtronic’s MiniMed go Smart Multiple Daily Injection app was approved for the use of patients aged ≥7 years with T1D or T2D, as well as for children between 2-6 years with adult supervision. The device integrates the InPen smart insulin pen and the Instinct sensor, both of which were developed by Abbott, to provide users with missed dose alerts to minimize glucose highs, action-oriented guidance in the event of a missed or miscalculated dose, and a dose calculator to help simplify decision-making.


VESPER-3: Positive Results of Long-Term GLP-1 PF’3944 in Overweight and Obesity Without T2D


Pfizer’s investigational ultra-long-acting, fully biased GLP-1 RA displayed substantial weight loss compared to placebo in patients with overweight or obesity but without T2D. VESPER-3, an ongoing 64-week trial, includes 4 separate titration and dosage arms and a placebo comparator. By week 28, arm 1 saw a 10% placebo-adjusted weight loss, while arm 3 exhibited 12.3%. Pfizer has announced that full data from the trial will be presented on June 6 at the American Diabetes Association’s 86th Scientific Sessions.


ACHIEVE-3: Orforglipron Achieves Superiority to Oral Semaglutide in Poorly Controlled T2D


Eli Lilly announced detailed results from ACHIEVE-3 on February 26, 2026. The trial demonstrated orforglipron’s superiority to oral semaglutide for the treatment of T2D inadequately controlled with metformin. Orforglipron led to an A1c reduction of 2.2% in the 36 mg treatment arm and by 1.9% in the 12 mg arm, compared to 1.1% and 1.4% in semaglutide 7 mg and 14 mg. Similarly, patients given orforglipron saw a body weight reduction of 9.2% in the 36 mg arm and 6.7% in the 12 mg arm, compared to 3.7% and 5.3% in the semaglutide 7 mg and 14 mg arms, respectively.


Retatrutide Delivers A1C Reduction, Weight Loss in Phase 3 TRANSCEND-T2D-1 Trial


The TRANSCEND-T2D-1 trial data, published on March 19, 2026, demonstrated Eli Lilly’s groundbreaking GIP/GLP-1/glucagon triple agonist and its efficacy as an adjunct to diet and exercise in patients with T2D and inadequate glycemic control. 3 separate doses of retatrutide were pitted against placebo in adults with T2D – patients given the 12 mg dose lost an average of 28.7% of their body weight at 68 weeks. Full data will be presented at the American Diabetes Association conference in June 2026.


Diabetes Dialogue: Orforglipron, Retatrutide, and Other GLP-1 Updates


In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss an onslaught of news regarding GLP-1 RAs and similar medications. Orforglipron’s exceptional results from ACHIEVE-3, retatrutide’s superiority to placebo in T2D, and early phase 2 data on Novo Nordisk’s investigative triple agonist UBT251 take center stage as Isaacs and Bellini cover the expanding landscape of these practice-changing medications.


Diabetes Dialogue: Oral Ozempic and the Risks of Compounding Formulas


In this episode, Isaacs and Bellini cover a landscape of oral GLP-1s, between Ozempic, Wegovy, and Rybelsus – the latter now known as Ozempic as well. Additionally, the cohosts discuss the controversy surrounding Hims and Hers, a nutrition/lifestyle company marketing lower-cost, compounded oral GLP-1s. The company is currently facing down a lawsuit by Novo Nordisk, given that they potentially infringed upon the latter’s proprietary SNAC technology. Isaacs and Bellini warn that similar formulations to the Hims and Hers line may lack regulatory oversights, potentially resulting in direct risk to patients.

Articles

Endocrinology entered 2026 with multiple FDA actions and pivotal readouts spanning diabetes, obesity, and hypothalamic obesity. Regulatory milestones included the first once-weekly basal insulin (insulin icodec) for T2D, label updates enabling clearer Afrezza starting-dose conversions in T1D, expansion of setmelanotide to acquired hypothalamic obesity, and clearance of a smart MDI support app integrating connected pen/sensor technology. Late-stage trials highlighted potent glycemic and weight effects from oral orforglipron versus oral semaglutide and from triple-agonist retatrutide, alongside encouraging obesity data for Pfizer’s ultra-long GLP-1 RA.

Catch up on FDA decisions, new GLP-1 agonists, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Strategic Alliance Partnership

Q1 2026 Recap: Endocrinology News and Updates

Mark G. Lebwohl, MD, the dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai,

Defining Treatment Goals and Addressing Unmet Needs in Psoriasis

In this episode, ‘Defining Treatment Goals and Addressing Unmet Needs in Psoriasis,’ the expert dermatologists explore the evolution of patient expectations and the clinical necessity of aggressive disease management. Dr. Mark Lebwohl explains that his primary objective aligns with the National Psoriasis Foundation treat to target guidelines, which aim for less than 1% body surface area involvement. He argues that this goal is vital because psoriasis is a systemic inflammatory condition rather than a localized skin issue. Dr. Lebwohl notes that severe psoriasis can triple the risk of heart attacks in young patients, making effective treatment essential for cardiovascular and joint health.

Dr. Tina Bhutani-Jacques adds that while patients may be hesitant to commit to lifelong therapy, the risks of under treatment often outweigh the potential side effects of modern medications. She points out that achieving total clearance is now a realistic possibility for many patients, though significant unmet needs remain. The experts identify specific challenges such as nail psoriasis and palmoplantar psoriasis, where current therapies still struggle to produce consistent results. They also discuss the need for better management of psoriatic arthritis and the pursuit of PASI 100 scores across more of the patient population. Reflecting on the history of the field, the doctors contrast the dangerous and less effective treatments of the past with the current landscape, concluding that striving for tighter disease control is a necessary standard of care to prevent long term comorbidities.

The next episode in this series, ‘The Role of TYK2 Inhibitors in Modern Psoriasis Care,’ features the panelists discussing the mechanism of action of TYK2 inhibitors and how they provide a highly selective oral alternative to injectable biologics. Dr. Bhutani-Jacques and Dr. Lebwohl explain how these agents block specific cytokine signaling while maintaining a favorable safety profile compared to traditional JAK inhibitors.

Videos

Expert dermatologists urge aggressive psoriasis control to prevent heart and joint risks, highlight unmet needs, and preview TYK2 inhibitors as a safer oral option.

Addressing Challenges in Psoriasis with Evolving Treatment Landscape

Welcome back to another HCPLive Peers & Perspectives series. In this episode titled, ‘Addressing Challenges in Psoriasis with Evolving Treatment Landscape,’ Dr. Tina Bhutani-Jacques joins Dr. Mark Lebwohl to discuss the current state of psoriasis care. The conversation centers on the emergence of TYK2 inhibitors as a distinct class of treatment and how these agents provide new opportunities for patient management.

Dr. Lebwohl reflects on the dramatic evolution of psoriasis therapy, noting that while practitioners now have approximately 15 highly effective options, the abundance of choices presents its own challenges. He emphasizes that selecting the right treatment is a scientific process rather than an art form. The decision depends heavily on individual patient factors including the extent of the disease and a wide array of comorbidities. Dr. Lebwohl highlights that common conditions such as obesity, joint pain, cardiovascular risk, diabetes, and inflammatory bowel disease significantly influence which medication is most appropriate for a specific person. He also notes the importance of screening for infections like HIV or tuberculosis before finalizing a treatment plan. The experts conclude that the complexity of the psoriasis patient population requires a nuanced approach to positioning newer oral agents like TYK2 inhibitors. This episode sets the stage for a deeper dive into the latest efficacy and safety data that help clinicians navigate these real world treatment hurdles.

In the next episode, ‘Defining Treatment Goals and Addressing Unmet Needs in Psoriasis’, panelists will continue their discussion on psoriasis and highlight the importance of the treat to target approach while identifying remaining gaps in care for difficult to treat areas like the palms and soles. The experts emphasize that achieving clear skin is not just about aesthetics but about reducing systemic inflammation and long term cardiovascular risks.

Explore how TYK2 inhibitors reshape psoriasis care, as experts weigh comorbidities, infection screening, and treat-to-target goals to overcome real-world treatment hurdles.

Ali Rezaie, MD, is medical director of the GI Motility Program at Cedars-Sinai.

New Study Raises Safety Concerns for Antidepressant Use in IBS

Management of irritable bowel syndrome (IBS) has undergone a notable evolution in recent decades, shifting from largely empirical, symptom-based treatment toward a more nuanced, mechanism-driven approach. However, as clinicians increasingly rely on long-term pharmacotherapy for a condition often diagnosed in early adulthood, questions around the durability and safety of these treatments have come into sharper focus.

A recent large-scale study led by Ali Rezaie, MD, medical director of the GI Motility Program at Cedars-Sinai, sought to address a critical gap in the literature surrounding the long-term mortality risk associated with commonly used IBS medications. His research utilized nearly 2 decades of electronic health records from > 650,000 US adults with IBS, making it the largest real-world study to examine the long-term safety of IBS treatments.

“One important thing about the irritable bowel syndrome is that a lot of patients are diagnosed in their 20s, 30s, or 40s. If you start them on a medication, this is not necessarily a curable disease, so they will be on that medication for years and decades,” Rezaie explained. “The issue is that when we do clinical trials using medications, they have a limited timeframe and they're generally small, so a rare side effect or long-term side effects will not pop up in those types of research. It's very important when we are treating patients with a specific medication to know whether there are risks associated with it.”

He and colleagues performed a retrospective cohort study using a nationwide US electronic health record database from January 2005 to January 2023. Their 1:1 propensity score-matched cohort included 669,083 adults with IBS. Patients were grouped by pharmacotherapy use, with subgroup analyses for IBS with diarrhea (IBS-D) and IBS with constipation (IBS-C). Rezaie noted the analysis accounted for more than 50 variables—including comorbidities, concomitant medications, demographics, and lifestyle factors—to minimize confounding.

Results showed antidepressant use was associated with an increased risk of all-cause mortality (hazard ratio [HR], 1.35; 95% CI, 1.26–1.45; mortality rate, 1.6% vs 1.0%) and remained consistent across antidepressant subclasses and demographic subgroups.

While the relative increase was approximately 30%, the absolute risk difference remained modest. However, given that IBS affects a substantial portion of the US population, Rezaie noted that even small absolute increases could translate into meaningful population-level impact.

“Individually, the risk is not that high, but if you think about the fact that more than 10% of the US population has irritable bowel syndrome, that 0.6% potentially can translate into a significant number of deaths that we can potentially induce by starting patients on antidepressants in an IBS, which is not a fatal disease by itself,” he explained.

Further analyses reinforced the robustness of these findings. Comparisons with active comparator groups, stratification by age, and evaluation of negative control conditions all supported the observed association. Additionally, a dose-response relationship emerged, with higher numbers of prescription refills correlating with greater mortality risk. Mechanistically, the study identified increased rates of known antidepressant-related adverse events, including falls, arrhythmias, heart failure, bleeding, and suicidal ideation, which may mediate this risk.

Of note, results additionally showed antispasmodic use was not linked to increased mortality (HR, 0.95; 95% CI, 0.89–1.00).

Subgroup analyses provided additional clinical insight. For IBS-D, cholestyramine/colestipol, eluxadoline, and rifaximin were not associated with mortality. However, diphenoxylate (HR, 1.89; 95% CI, 1.02–3.51) and loperamide (HR, 2.39; 95% CI, 1.48–3.90) show increased mortality risk. For IBS-C, polyethylene glycol-3350 and secretagogues showed no significant association with mortality.

Rezaie emphasized the implications for clinical practice. Because IBS is a chronic, non-fatal condition often requiring decades of management, long-term safety data are essential for informed decision-making. He noted that current guidelines largely lack such data and continue to emphasize symptom control without fully addressing potential long-term harms. These findings, he suggested, should prompt more transparent discussions with patients and may ultimately inform future guideline updates.

“I guess the bottom line is that when we are starting patients on medications for irritable bowel syndrome, along with the safety data that we have from clinical trials, I think it's fair to describe the long term side effects of these medications with the patients for more informed decision making,” he said “Also, I think right now, societal guidelines are are not incorporating long term side effects because there's no data, and hopefully this [research] will guide some of those recommendations and societal guidelines.”

Editors’ note: Rezaie reports relevant disclosures with Bausch Health, Ardelyx, and others.

 Association of pharmacotherapy with all-cause mortality among patients with irritable bowel syndrome. 

https://doi.org/10.1038/s43856-026-01498-6

Cedars-Sinai Medical Center. Some common IBS treatments linked to higher risk of death. EurekAlert! April 8, 2026. Accessed April 9, 2026. 

https://www.eurekalert.org/news-releases/1122913

New long-term data link antidepressant use in IBS to higher mortality risk. Rezaie explains key findings and clinical implications.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Are We Overlooking Long-Term Risks in IBS Management? New 20-Year Safety Data, With Ali Rezaie, MD

Despite being a relatively quiet first quarter in terms of approvals from the 

, cardiology had no shortage of groundbreaking developments over the first 3 months of 2026. Between major trial results and substantial overhauling of guidelines, everything from 

 and myocardial infarction saw significant advancements. Additionally, the American College of Cardiology (ACC) Scientific Sessions 2026, conducted in New Orleans, Louisiana, from March 28-30, brought with it a tremendous amount of news across a plethora of specialties.

With so much news coming out of the start of the year, the editorial team at 

 has put together a collection of the most impactful headlines from January to March of 2026. Catch up with any news you may have missed below:

OCEANIC-STROKE: Asundexian Reduces Stroke Risk Without Increasing Bleeding, With Andrew Russman, DO


OCEANIC-STROKE concluded in February of 2026, indicating the superiority of asundexian to placebo in preventing 

 in patients after non-cardioembolic ischemic stroke or high-risk transient ischemic attack. A total of 12,327 patients were enrolled in the trial – among these patients, the team noted that asundexian reduced ischemic stroke by 26% with no increase in risk of ISTH major bleeding. This finding was consistent across all subgroups. Additionally, secondary endpoints highlighted asundexian’s beneficial effect on ischemic and hemorrhagic stroke with no major increase in the ISTH major bleeding rate.


RSV Vaccine Demonstrates Cardioprotective Effects, Reduces MACE and Hospitalizations, With Deepak Bhatt, MD, MPH


In February of 2026, GSK published a study investigating its Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted – marketed under the name Arexvy – to display its efficacy in reducing major adverse cardiovascular events and RSV-related hospitalizations in adults over 60. The retrospective cohort study was presented at RSVVW’26, the 9th Conference of the Respiratory Syncytial Virus Foundation, and enrolled a total of 520,440 patients. The vaccine demonstrated 20.4% effectiveness in patients with existing cardiovascular disease, demonstrating its substantial benefit in preventing RSV-related cardiovascular events.


CORALreef Lipids: Enlicitide Reduces LDL-C in Patients With ASCVD, With Ann Marie Navar, MD, PhD


The final data from CORALreef Lipids were presented in February of 2026, displaying enlicitide decanoate’s efficacy in lowering LDL-C versus placebo in patients with a major 

atherosclerotic cardiovascular disease (ASCVD)

 event. Patients across both the treatment and placebo arms displayed substantial treatment adherence across the full 52 weeks, inspiring hope among the participating investigators that the comparative simplicity of oral enlicitide will overcome prescription inertia in dyslipidemia management.


ADA’s Obesity Association Releases Guidelines for Use of Obesity Medications


On January 13, 2026, the Obesity Association, a subdivision of the American Diabetes Association, published a new section in the 

Standards of Care in Overweight and Obesity

, discussing pharmacotherapy’s updated role in reducing weight and improving outcomes. The document spotlights weight-promoting medications for major disorders such as diabetes and 

, positing alternatives to avoid excess weight gain and thereby avert cardiovascular damage. Additionally, the writers emphasized the importance of intensive behavioral therapy.

Updated ACC/AHA Dyslipidemia Guidelines Incorporate LDL-C Goals, Lp(a) Focus, With Deepak Bhatt, MD, MPH


On March 13, 2026, the ACC and the American Heart Association (AHA) released an updated clinical guideline for the management of dyslipidemia. The document replaced the 2018 guidelines on blood cholesterol management. The new document emphasizes the testing of Lp(a) levels as a COR I suggestion, as well as reinstating targeted LDL-C goals after years of percent LDL-C reductions to monitor patient progress. These goals are assigned based on the PREVENT risk calculator.


New Pulmonary Embolism Guidelines Highlight Progress, Encourage Research, With Mark Creager, MD


Published on February 19, 2026, the ACC and AHA put out a clinical practice guideline for acute pulmonary embolism (PE) treatment, representing the first ever published from these institutions. The guide includes a new classification scheme of 5 categories, equivalent to low to high risk of adverse outcomes. The document also encourages the use of direct oral anticoagulant medications over vitamin K antagonists in eligible patients.


Evolocumab Reduces CV Risk in Non-Atherosclerotic Patients With Diabetes, With Nicholas Marston, MD, MPH


A secondary analysis of the VESALIUS-CV trial, presented at ACC.26, has revealed evolocumab’s capacity to reduce the risk of first major adverse cardiovascular events in patients with diabetes but no known significant atherosclerosis. The analysis incorporated a composite primary endpoint of coronary heart disease death, myocardial infarction, or ischemic stroke (3-P MACE), while another included ischemia-driven arterial revascularization on top of the previous 3. Ultimately, 3-P MACE occurred in 83 patients in the treatment arm compared to 117 in placebo, while 4-P MACE occurred in 127 in the treatment arm and 178 in the placebo arm.


LV Unloading Before Delayed PCI Reduces Infarct Size by 1%, With Gregg Stone, MD, and Navin Kapur, MD


The STEMI-Door to Unload (DTU) study may not have achieved statistical significance, but a 1% reduction in infarct size after left ventricular unloading and a 30-minute delay prior to percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) presents a promising path for future research. Presented at ACC.26, this trial demonstrates a significant opportunity for the therapy moving forward, as the device not increasing infarct size establishes its safety, if not its efficacy.

CHAMPION-AF: Left Atrial Appendage Closure Noninferior to NOACs


Device-based left atrial appendage closure (LAAC) was noninferior to non-vitamin K antagonist oral anticoagulant (NOAC) therapy for the prevention of adverse events in patients with 

, according to results from the CHAMPION-HF trial. Patients were given either the Watchman FIx device or an approved NOAC, after which they were administered short-term antithrombotic therapy for 3 months before transitioning to antiplatelet therapy. At 3 years, the primary endpoint – a composite of cardiovascular death, stroke, or systemic embolism, occurred in 81 patients in the device group and 65 patients in the NOAC group, yielding a difference of 0.9%.

Cardiology’s early-2026 landscape featured pivotal trial readouts, new pharmacotherapy guidance, and major ACC/AHA guideline revisions, alongside high-impact data from ACC.26. Factor XIa inhibition with asundexian reduced recurrent ischemic stroke without excess major bleeding, while RSV vaccination showed meaningful cardiovascular event mitigation in older adults. Novel lipid-lowering strategies advanced, including oral enlicitide and expanded PCSK9 benefit signals. Guideline changes emphasized obesity pharmacotherapy, renewed LDL-C targets, routine Lp(a) testing, and a first ACC/AHA acute PE framework favoring DOACs.

Catch up on major trial results, groundbreaking guideline updates, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Atherosclerotic Cardiovascular Disease

Arrhythmia

Dyslipidemia

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Structural Heart Disease

Cardiomyopathy

Venous Thromboembolism

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

Q1 2026 Recap: Cardiology News and Updates

Simon Davies, MD, is  a consultant nephrologist at the University Hospital of North Midlands and Professor of Nephrology and Dialysis Medicine, as well as director of the Institute for Applied Clinical Sciences at Keele University.

Davies breaks down the gaps to at-home dialysis access and the future of global collaboration. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Chronic Kidney Disease

Gaps in Home Dialysis Access Persist Globally, With Simon Davies, MD

Phase 3 ONWARD data for the investigational TYK2 inhibitor envudeucitinib join a rapidly crowding oral psoriasis space.


Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

How Envudeucitinib May Fit Into the Evolving Oral Psoriasis Landscape, With Andrew Blauvelt, MD, MBA

In the final episode, ‘Risk-Based Management in Hypercortisolism,’ the panelists explored how to approach hypercortisolism management in the absence of widely accessible, targeted therapies, emphasizing a risk-based treatment paradigm. 

Video Series

Risk-Based Management in Hypercortisolism

In ‘Emerging Therapies in Hypercortisolism,’ our panel explores the evolving therapeutic landscape for hypercortisolism and the future direction of treatment development.

Emerging Therapies in Hypercortisolism

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

March 2026 endocrinology updates include key FDA approvals, advances in diabetes and obesity therapies, and innovations in insulin delivery and rare disease care.

7 Endocrinology Headlines You Missed in March 2026

In this episode, ‘Hypercortisolism and Cardiovascular Risk Management,’ the panelists explore the broader implications of hypercortisolism on cardiovascular risk and the role of cardiologists in comprehensive patient management.

Hypercortisolism and Cardiovascular Risk Management

This episode, titled ‘Hypercortisolism Treatment and Care Pathways,’ features panelists discussing the management of hypercortisolism following diagnosis, with a focus on the roles of cardiologists and endocrinologists in coordinating care. 

Hypercortisolism Treatment and Care Pathways

In ‘Hypertension Management in Hypercortisolism,’our panel explores the clinical implications of emerging data on hypercortisolism and outline a forward-looking approach to hypertension management.

Hypertension Management in Hypercortisolism

In this episode, ‘Hypercortisolism and Guideline Implications,’ the panelists explore the implications of emerging hypercortisolism data for clinical guidelines and routine cardiovascular practice.

Hypercortisolism and Guideline Implications

This episode, titled ‘Recognizing Hypercortisolism in Cardiology,’ features panelists discuss the clinical implications of emerging hypercortisolism data for cardiologists and how these findings should influence everyday practice. 

Latest News

Q1 2026 Recap: Endocrinology News and Updates

Defining Treatment Goals and Addressing Unmet Needs in Psoriasis

Addressing Challenges in Psoriasis with Evolving Treatment Landscape

Are We Overlooking Long-Term Risks in IBS Management? New 20-Year Safety Data, With Ali Rezaie, MD

Q1 2026 Recap: Cardiology News and Updates